Xcout Intel
Scarlet Therapeutics
Scarlet Therapeutics, founded in 2021 and headquartered in Bristol, United Kingdom, is developing a pioneering platform that generates novel red blood cell-based therapeutics to treat a wide range of diseases.
Subscribe to see Scarlet Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Scarlet Therapeutics at a glance
Scarlet Therapeutics is a biotech company headquartered in United Kingdom. Its most recent funding round, Seed, raised $4.4M in May 2026. Xcout tracks 3 named people at Scarlet Therapeutics, including Alistair Irvine (CEO).
Scarlet Therapeutics leadership
- Alistair IrvineCEO
- Ash ToyeProfessor
- Jan FrayneProfessor
Scarlet Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $4.4M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Scarlet Therapeutics competitors
A few of Scarlet Therapeutics's closest competitors — see the full list of competitors and alternatives →
Ferrosa Therapeutics AG is a Swiss biotechnology company founded in Basel, Switzerland, focusing on developing novel therapeutics to treat anemia and related conditions.
Based in Watertown, Massachusetts, Disc Medicine, Inc. operates as a clinical-stage biotechnology company. Its core mission involves the discovery, development, and commercialization of novel therapeutic solutions for individuals suffering from serious hematological diseases. The company is actively constructing a pipeline of drug candidates, designed to address a variety of these conditions by precisely targeting fundamental biological mechanisms related to red blood cell biology, particularly heme biosynthesis and iron homeostasis.
Carmine Therapeutics, Inc. is an EVX Ventures company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies.
Modus Therapeutics AB is a Swedish clinical-stage biotechnology company developing sevuparin, a proprietary polysaccharide drug candidate with anti-adhesive and anti-inflammatory properties. Its work has focused on treatments for severe inflammatory and vascular conditions, including sickle cell disease, serving patients with serious unmet medical needs.
Argonaute RNA is a therapeutics company headquartered in Bristol, United Kingdom, pursuing opportunities in RNA-based treatments.
Skylark Bio is a biotechnology company developing precision-targeted, locally delivered gene therapies to treat genetic hearing loss and other single-gene disorders. The company's platform aims to restore natural biological processes and hearing function, addressing conditions that affect children and individuals with genetic communication impairments.
Get Scarlet Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Scarlet Therapeutics in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access